about
Cirrhotic cardiomyopathyNon-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayCellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosisCellular and molecular mechanisms in the pathogenesis of liver fibrosis: An updateAnandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA inductionEndocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease.Pathobiology of liver fibrosis: a translational success storyNew insights on the role of the endocannabinoid system in the regulation of energy balance.Crystal Structure of the Human Cannabinoid Receptor CB1.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.Modulation of Human Peripheral Blood Mononuclear Cell Signaling by Medicinal Cannabinoids.Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.Medical marijuana for digestive disorders: high time to prescribe?Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization.Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.Cannabinoid Receptor 1 Mediates Homing of Bone Marrow-Derived Mesenchymal Stem Cells Triggered by Chronic Liver Injury.Hepatic stellate cells as key target in liver fibrosis.Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus-coinfected Women.Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage.Daytime-Dependent Changes of Cannabinoid Receptor Type 1 and Type 2 Expression in Rat Liver.New medical treatment strategies for nonalcoholic steatohepatitis.The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway.Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice.4-O'-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice.In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications?Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration.Targeting cannabinoid receptors in hepatocellular carcinoma?The Role of Cannabinoids in the Setting of Cirrhosis.Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease.Sequential Synthesis, Olfactory Properties, and Biological Activity of Quinoxaline Derivatives.Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors
P2860
Q26778048-75645D78-D259-426E-BBF6-085868EAC7DEQ26800894-E0BD13C8-682F-4738-9789-6FE7F074BB60Q27021577-94060FA9-6C5A-41DA-9A8F-CB26E1B1F939Q27027703-1C705D5E-B059-4BB4-BE38-42495C1EF642Q31156796-7AC593B8-0B5F-4176-87EC-5EE5D116CBA9Q33597839-5BDAFFE0-719B-4CDA-BF82-6176E5AD4A97Q34462733-44490F8E-FD7B-4466-B8AD-945B62466120Q34494301-42810FCF-0609-4883-B23C-F354193F130BQ34543208-FC65DFB7-1A2D-4A38-8D5A-5A677F4B9430Q34647400-E0A5B04A-F852-48CE-9921-7D5A665228F2Q35585455-094568F3-DC78-4A86-A13A-5DD0166EBD98Q37601380-438EE870-5056-40EF-8AB0-8051BAAC26BDQ38157936-7CD4D399-B8A9-492C-884F-E5EA70D1C9B5Q38246940-EA8FA4E5-97BC-4166-BCBA-78E33FA64D3EQ38555120-06ABF5DD-E61E-4922-B53A-5AB24E7D90AFQ38939502-E54FD33E-95C4-49B3-95B4-A21BB195BF2AQ39877226-966371B0-E145-414E-9A9F-F1CE53FD4758Q40200602-4D40F878-689C-4DE5-956F-6208CFA9546AQ40659740-95321142-6177-47B8-8DA6-90341CC39144Q41534560-34A1BA60-7307-4A98-907E-E53EEB215617Q41661314-E723F831-374F-4D30-B104-24230392AFB9Q42175498-878C6666-9246-4042-8AED-C0F8A496E259Q42534041-582DBCAB-C483-42C3-9104-4516A0865031Q47149284-A3A0FFCB-A5F8-468C-A59B-B5A15A39FAA0Q50901294-6EC76001-6932-4605-BAD4-FFCE61CC1DC5Q50998617-CA48F94D-7B6C-42F3-8ED5-023133EC79EDQ53615365-575EF354-4E9B-4A6B-AD16-C22532E9F0EBQ53764023-8E9A10E4-C0A9-4390-AE26-7D420BE93395Q55415931-5BACF584-7854-4534-94C2-DC3A7404CEC1Q55452630-6D30A4FE-A2F3-4705-9F25-43705ADD3908Q55668804-60FCB7AF-0097-4273-A07F-D723A485CD31Q58580945-129F80EE-F35C-4307-92AF-22FF571D9F77
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cannabinoid signaling and liver therapeutics.
@ast
Cannabinoid signaling and liver therapeutics.
@en
Cannabinoid signaling and liver therapeutics.
@nl
type
label
Cannabinoid signaling and liver therapeutics.
@ast
Cannabinoid signaling and liver therapeutics.
@en
Cannabinoid signaling and liver therapeutics.
@nl
prefLabel
Cannabinoid signaling and liver therapeutics.
@ast
Cannabinoid signaling and liver therapeutics.
@en
Cannabinoid signaling and liver therapeutics.
@nl
P1476
Cannabinoid signaling and liver therapeutics.
@en
P2093
Ariane Mallat
Fatima Teixeira-Clerc
P304
P356
10.1016/J.JHEP.2013.03.032
P577
2013-04-06T00:00:00Z